Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.42 |
| ▸ | RAF1 | P04049 | 8/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546081 | 0.91 | KDR (0.43) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL544981 | 0.88 | KDR (0.43) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL5428304 | 0.83 | RAF1 (0.44) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL5429952 | 0.81 | BRAF (0.45) | KDRRAF1BRAFFLT1SRC | |
| SCHEMBL5423039 | 0.81 | BRAF (0.60) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL545498 | 0.78 | RAF1 (0.59) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL545068 | 0.74 | RAF1 (0.43) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL5416351 | 0.74 | RAF1 (0.45) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL5418586 | 0.72 | RAF1 (0.51) | KDRRAF1BRAFFLT1ABL1 | |
| SCHEMBL5422272 | 0.71 | KDR (0.53) | KDRRAF1BRAFABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | KDR 1264/4885RAF1 198/4885BRAF 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.